F2-isoprostanes as biomarkers of late-onset Alzheimer's disease

Journal of Molecular Neuroscience

Volumn 33, Issue 1, 2007, Pages 114-119

  Montine, Thomas J ^a,b   Quinn, Joseph ^b   Kaye, Jeffrey ^b   Morrow, Jason D ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Dementia; F2 Isoprostanes; Latency; Prodrome

Indexed keywords

BIOLOGICAL MARKER; FREE RADICAL; ISOPROSTANE DERIVATIVE; LIPID;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; DEMENTIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DOWN SYNDROME; GENE MUTATION; HUMAN; LIPID BLOOD LEVEL; LIPID BRAIN LEVEL; LIPID DEGRADATION; NONHUMAN; ONSET AGE; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVIEW; RISK FACTOR; URINE LEVEL;

ALZHEIMER DISEASE; ANTIOXIDANTS; BIOLOGICAL MARKERS; BRAIN; DIETARY SUPPLEMENTS; FREE RADICALS; HUMANS; ISOPROSTANES;

EID: 35348817935     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-007-0044-1     Document Type: Review

References (51)

1. Arriagada, P. V., Marzloff, K., & Hyma, B. T. (1992). Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology, 42, 1681-1688.
2. Berg, L., McKeel, D. W., Miller, J. P., Baty, J., & Morris, J. C. (1993) Neuropathological indexes of Alzheimer's disease in demented and nondemented persons aged 80 years and older. Archives of Neurology, 50, 349-358.
3. Bohnstedt, K. C., Karlberg, B., Wahlund, L., Jonhagen, M. E., Basun, H., & Schmidt, S. (2003). Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry. Journal of Chromatography B Analytical Technology Biomedical Life Science, 796, 11-19.
4. Brookmeyer, R., Gray, S., & Kawas, C. (1998). Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. American Journal of Public Health, 88, 1337-1342.
5. Crystal, H. A., Dickson, D. W., Sliwinski, M. J., Lipton, R. B., Grober, E., Marks-Nelson, H., et al. (1993) Pathological markers associated with normal aging and dementia in the elderly. Annals of Neurology, 34, 566-573.
6. Davis, D. G., Schmitt, F. A., Wekstein, D. R., & Markesbery, W. (1999) Alzheimer neuropathological alterations in aged cognitively normal subjects. Journal of Neuropathology and Experimental Neurology, 58, 376-388.
7. de Leon, M. J., Desanti, S., Zinkowski, R., Mehta, P. D., Pratico, D., Segal, S., et al. (2006). Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiology of Aging, 27, 394-401.
8. Ernst, R. L., & Hay, J. W. (1994). The US economic and social costs of Alzheimer's disease revisited. American Journal of Public Health, 84, 1261-1264.
9. Evans, D. A. (1990). Estimated prevalence of Alzheimer's disease in the United States. Milbank Quarterly, 68, 267-289.
10. Feillet-Coudray, C., Tourtauchaux, R., Niculescu, M., Rock, E., Tauveron, I., Alexandre-Gouabau, M. C., et al. (1999). Plasma levels of 8-epiPGF2alpha, an in vivo marker of oxidative stress, are not affected by aging or Alzheimer's disease. Free Radical Biology & Medicine, 27, 463-469.
11. Galasko, D., Katzman, R., Salmon, D., & Hansen, L. (1996). Clinical and neuropathological findings in Lewy body dementias. Brain and Cognition, 31, 166-175.
12. Green, M. S., Kaye, J. A., & Ball, M. J. (2000) The Oregon brain aging study: Neuropathology accompanying health aging in the oldest old. Neurology, 54, 105-113.
13. Hardy, J., & Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science, 297, 353-356.
14. Haroutunian, V., Purohit, D. P., Perl, D. P., Marin, D., Khan, K., Lantz, M., et al. (1999). Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Archives of Neurology, 56, 713-718.
15. Hulette, C. M., Welsh-Bohmer, K. A., Murray, M. G., Saunders, A. M., Mash, D. C., & McIntyre, L. M. (1998) Neuropathological and neuropsychological changes in "normal" aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. Journal of Neuropathology and Experimental Neurology, 57, 1168-1174.
16. Katzman, R. (1976). Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Archives of Neurology, 33, 217-218.
17. Martin, B. K., Meinert, C. L., & Breitner, J. C. (2002). Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clinical Trials, 23, 93-99.
18. McCormick, W. C., Hardy, J., Kukull, W. A., Bowen, J. D., Teri, L., Zitzer, S., et al. (2001). Healthcare utilization and costs in managed care patients with Alzheimer's disease during the last few years of life. Journal of the American Geriatrics Society, 49, 1156-1160.
19. Montine, T. J., Beal, M. F., Cudkowicz, M. E., Brown, R. H., O'Donnell, H., Margolin, R. A., et al. (1999a). Increased cerebrospinal fluid F2-isoprostane concentration in probable Alzheimer's disease. Neurology, 52, 562-565.
20. Montine, T. J., Beal, M. F., Robertson, D., Cudkowicz, M. E., Biaggioni, I., O'Donnell, H., et al. (1999b). Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease. Neurology, 52, 1104-1105.
21. Montine, T. J., Kaye, J. A., Montine, K. S., McFarland, L., Morrow, J. D., & Quinn, J. F. (2001). CSF Ab42, tau, and F2-isoprostane concentrations in patients with Alzheimer's disease, other dementias, and age-matched controls. Archives of Pathology and Laboratory Medicine, 125, 510-512.
22. Montine, T. J., Markesbery, W. R., Morrow, J. D., & Roberts, L. J. (1998). Cerebrospinal fluid F2-isoprostanes are increased in Alzheimer's disease. Annals of Neurology, 44, 410-413.
23. Montine, T. J., Markesbery, W. R., Zackert, W., Sanchez, S. C., Roberts, L. J., & Morrow, J. D. (1999c). The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neuritic plaques or neurofibrillary tangles, or with APOE genotype in Alzheimer's disease patients. American Journal of Pathology, 155, 863-868.
24. Montine, T. J., Neely, M. D., Quinn, J. F., Beal, M. F., Markesbery, W. R., Roberts, L. J., II, et al. (2002a). Lipid peroxidation in aging brain and Alzheimer's disease. Free Radical Biology & Medicine, 33, 620-626.
25. Montine, T. J., Quinn, J. F., Milatovic, D., Silbert, L. C., Dang, T., Sanchez, S., et al. (2002b). Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Annals of Neurology, 52, 175-179.
26. Montine, T. J., Shinobu, L., Montine, K. S., Roberts, L. J., II, Beal, M. F., & Morrow, J. D. (2000). No difference in plasma or urine F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease, and controls. Annals of Neurology, 48, 950.
27. Montine, T. J., Sidell, K. S., Crews, B. C., Markesbery, W. R., Marnett, L. J., Roberts, L. J., et al. (1999d). Elevated cerebrospinal fluid prostaglandin E2 levels in patients with probable Alzheimer's disease. Neurology, 53, 1495-1498.
28. Morris, J. C., & Price, A. L. (2001). Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. Journal of Molecular Neuroscience, 17, 101-118.
29. Morrow, J. D., Hill, K. E., Burk, R. F., Nammour, T. M., Badr, K. F., & Roberts, L. J. (1990). A series of prostaglandin-like compounds produced in vivo in humans by a non-cyclooxygenase, free radical catalyzed mechanism. Proceedings of the National Academy of Sciences of the United States of America, 87, 9383-9387.
30. Morrow, J. D., & Roberts, L. J., II (1994). Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical catalyzed mechanism. Methods in Enzymology, 233, 163-174.
31. Petersen, R., Doody, R., Kurz, A., Mohs, R., Morris, J., Rabins, P., et al. (2001). Current concepts in mild cognitive impairment. Archives of Neurology, 58, 1985-1982.
32. Petrovitch, H., White, L. R., Izmirilian, G., Ross, G. W., Havlik, R. J., Markesbery, W., et al. (2000) Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: The HAAS. Honolulu-Asia aging Study. Neurobiology of Aging, 21, 57-62.
33. Porter, N. A., Caldwell, S. E., & Mills, K. A. (1995) Mechanisms of free radical oxidation of unsaturated lipids. Lipids, 30, 277-290.
34. Pratico, D., Barry, O. P., Lawson, J. A., Adiyaman, M., Hwang, S. W., Khanapure, S. P., et al. (1998a). IPF2-alpha-I - an index of lipid peroxidation in humans. Proceedings of the National Academy of Sciences, 95, 3449-3454.
35. Pratico, D., Clack, C. M., Lee, V. M. Y., Trojanowski, J. Q., Rokach, J., & FitzGerald, G. (2000) Increased 8,12-iso-iPF2a-IV in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity. Annals of Neurology, 48, 809-812.
36. Pratico, D., Clark, C. M., Liun, F., Rokach, J., Lee, V. Y., & Trojanowski, J. Q. (2002). Increase of brain oxidative stress in mild cognitive impairment: A possible predictor of Alzheimer disease. Archives of Neurology, 59, 972-976.
37. Pratico, D., Lee, V. M., Trojanowski, J. Q., Rokach, J., & Fitzgerald, G. A. (1998b). Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB Journal, 12, 1777-1784.
38. Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991). The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiology of Aging, 12, 295-312.
39. Price, J. L., & Morris, J. C. (1999). Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Annals of Neurology, 45, 358-368.
40. Quinn, J. F., Montine, K. S., Moore, M., Morrow, J. D., Kaye, J. A., & Montine, T. J. (2004) Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. Journal of Alzheimer's Disease, 6, 93-97.
41. Reich, E. E., Markesbery, W. R., Roberts, L. J., 2nd, Swift, L. L., Morrow, J. D., & Montine, T. (2001) Brain regional quantification of F-ring and D/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. American Journal of Pathology, 158, 293-297.
42. Riley, K. P., Snowdon, D. A., & Markesbery, W. R. (2002). Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: Findings from the nun study. Annals of Neurology, 51, 567-577.
43. Schmitt, F. A., Davis, D. G., Wekstein, D. R., Smith, C. D., Ashford, J. W., & Markesbery, W. R. (2000). "Preclinical" AD revisited. Neuropathology of cognitively normal older adults. Neurology, 55, 370-376.
44. Strittmatter, W. J., & Roses A. D. (1995). Apolipoprotein E and Alzheimer's disease. Proceedings of the National Academy of Sciences, 92, 4725-4727.
45. Tsuang, D. W., & Bird, T. D. (2002). Genetics of dementia. Medical Clinics of North America, 86, 591-614.
46. Tuppo, E. E., Forman, L. J., Spur, B. W., Chan-Ting, R. E., Chopra, A., & Cavalieri, T. A. (2001). Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease. Brain Research Bulletin, 54, 565-568.
47. Waddington, E., Croft, K., Clarnette, R., Mori, T., & Martins, R. (1999). Plasma F2-isoprostane levels are increased in Alzheimer's disease: Evidence of increased oxidative stress in vivo. Alzheimer's Reports, 2, 277-282.
48. Welch, H. G., Walsh, J. S., & Larson, E. B. (1992). The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort. Journal of the American Geriatrics Society, 40, 221-224.
49. White, L., Petrovitch, H., Hardman, J., Nelson, J., Davis, D., Ross, G., et al. (2002). Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. Annals of the New York Academy of Sciences, 977, 9-23.
50. Xuereb, J. H., Brayne, C., Dufouil, C., Gertz, H., Wischik, C., Harrington, C., et al. (2000). Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Annals of the New York Academy of Sciences, 903, 490-496.
51. Zandi, P. P., Anthony, J. C., Khachaturian, A. S., Stone, S. V., Gustafson, D., Tschanz, J. T., et al. (2004) Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: The Cache County Study. Archives of Neurology, 61, 82-88.